Literature DB >> 24411819

A longitudinal, randomized, controlled trial of advance care planning for teens with cancer: anxiety, depression, quality of life, advance directives, spirituality.

Maureen E Lyon1, Shana Jacobs2, Linda Briggs3, Yao Iris Cheng4, Jichuan Wang4.   

Abstract

PURPOSE: To test the feasibility, acceptability and safety of a pediatric advance care planning intervention, Family-Centered Advance Care Planning for Teens With Cancer (FACE-TC).
METHODS: Adolescent (age 14-20 years)/family dyads (N = 30) with a cancer diagnosis participated in a two-armed, randomized, controlled trial. Exclusion criteria included severe depression and impaired mental status. Acceptability was measured by the Satisfaction Questionnaire. General Estimating Equations models assessed the impact of FACE-TC on 3-month post-intervention outcomes as measured by the Pediatric Quality of Life Inventory 4.0 Generic Core Scale, the Pediatric Quality of Life Inventory 4.0 Cancer-Specific Module, the Beck Depression and Anxiety Inventories, the Spiritual Well-Being Scale of the Functional Assessment of Chronic Illness Therapy-IV, and advance directive completion.
RESULTS: Acceptability was demonstrated with enrollment of 72% of eligible families, 100% attendance at all three sessions, 93% retention at 3-month post-intervention, and 100% data completion. Intervention families rated FACE-TC worthwhile (100%), whereas adolescents' ratings increased over time (65%-82%). Adolescents' anxiety decreased significantly from baseline to 3 months post-intervention in both groups (β = -5.6; p = .0212). Low depressive symptom scores and high quality of life scores were maintained by adolescents in both groups. Advance directives were located easily in medical records (100% of FACE-TC adolescents vs. no controls). Oncologists received electronic copies. Total Spirituality scores (β = 8.1; p = .0296) were significantly higher among FACE-TC adolescents versus controls. The FACE-TC adolescents endorsed the best time to bring up end-of-life decisions: 19% before being sick, 19% at diagnosis, none when first ill or hospitalized, 25% when dying, and 38% for all of the above.
CONCLUSIONS: Family-Centered Advance Care Planning for Teens With Cancer demonstrated feasibility and acceptability. Courageous adolescents willingly participated in highly structured, in-depth pediatric advance care planning conversations safely.
Copyright © 2014 Society for Adolescent Health and Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adolescent; Advance care planning; Advance directive; African-American; Cancer; Communication; Decision making; End of life; Family intervention; Pediatric palliative care

Mesh:

Year:  2014        PMID: 24411819     DOI: 10.1016/j.jadohealth.2013.10.206

Source DB:  PubMed          Journal:  J Adolesc Health        ISSN: 1054-139X            Impact factor:   5.012


  35 in total

Review 1.  Psychological interventions for parents of children and adolescents with chronic illness.

Authors:  Christopher Eccleston; Emma Fisher; Emily Law; Jess Bartlett; Tonya M Palermo
Journal:  Cochrane Database Syst Rev       Date:  2015-04-15

2.  Taboo Topics in Adolescent and Young Adult Oncology: Strategies for Managing Challenging but Important Conversations Central to Adolescent and Young Adult Cancer Survivorship.

Authors:  Giselle K Perez; John M Salsman; Kaitlyn Fladeboe; Anne C Kirchhoff; Elyse R Park; Abby R Rosenberg
Journal:  Am Soc Clin Oncol Educ Book       Date:  2020-03

3.  Feasibility of Conducting a Palliative Care Randomized Controlled Trial in Children With Advanced Cancer: Assessment of the PediQUEST Study.

Authors:  Veronica Dussel; Liliana Orellana; Natalie Soto; Kun Chen; Christina Ullrich; Tammy I Kang; Jeffrey R Geyer; Chris Feudtner; Joanne Wolfe
Journal:  J Pain Symptom Manage       Date:  2015-01-30       Impact factor: 3.612

Review 4.  The importance of early involvement of paediatric palliative care for patients with severe congenital heart disease.

Authors:  Sophie Bertaud; David F A Lloyd; Joanna Laddie; Reza Razavi
Journal:  Arch Dis Child       Date:  2016-04-21       Impact factor: 3.791

Review 5.  Respecting the spiritual side of advanced cancer care: a systematic review.

Authors:  Katherine M Piderman; Simon Kung; Sarah M Jenkins; Terin T Euerle; Timothy J Yoder; Gracia M Kwete; Maria I Lapid
Journal:  Curr Oncol Rep       Date:  2015-02       Impact factor: 5.075

6.  The Factor Structure of the Spiritual Well-Being Scale in Veterans Experienced Chemical Weapon Exposure.

Authors:  Hamid Sharif Nia; Saeed Pahlevan Sharif; Christopher Boyle; Ameneh Yaghoobzadeh; Bahram Tahmasbi; G Hussein Rassool; Mozhgan Taebei; Mohammad Ali Soleimani
Journal:  J Relig Health       Date:  2018-04

7.  Implementation and Impact of Patient Lay Navigator-Led Advance Care Planning Conversations.

Authors:  Gabrielle B Rocque; J Nicholas Dionne-Odom; Chao-Hui Sylvia Huang; Soumya J Niranjan; Courtney P Williams; Bradford E Jackson; Karina I Halilova; Kelly M Kenzik; Kerri S Bevis; Audrey S Wallace; Nedra Lisovicz; Richard A Taylor; Maria Pisu; Edward E Partridge; Thomas W Butler; Linda A Briggs; Elizabeth A Kvale
Journal:  J Pain Symptom Manage       Date:  2017-01-03       Impact factor: 3.612

8.  A new measure for end of life planning, preparation, and preferences in Huntington disease: HDQLIFE end of life planning.

Authors:  Noelle E Carlozzi; E A Hahn; S A Frank; J S Perlmutter; N D Downing; M K McCormack; S Barton; M A Nance; S G Schilling
Journal:  J Neurol       Date:  2017-11-15       Impact factor: 4.849

9.  Symptoms and Distress in Children With Advanced Cancer: Prospective Patient-Reported Outcomes From the PediQUEST Study.

Authors:  Joanne Wolfe; Liliana Orellana; Christina Ullrich; E Francis Cook; Tammy I Kang; Abby Rosenberg; Russ Geyer; Chris Feudtner; Veronica Dussel
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

10.  Deeper Conversations Need Not Wait Until the End.

Authors:  Lori Wiener; Chris Feudtner; Pamela Hinds; Joanne Wolfe; Jennifer Mack
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.